The Edelman Laboratory uses elements of continuum mechanics, digital signal processing, molecular biology and polymeric controlled release technology to examine the cellular and molecular mechanisms that transform stable coronary-artery disease to unstable coronary syndromes. Tissue-generated cells, for example, deliver growth factors and growth inhibitors for the study and potential treatment of accelerated arterial disease following angioplasty and bypass surgery. The laboratory holds patents for drug-delivery devices, tissue-engineered implants, and new drug formulations.